Current progress in neoantigen-based dendritic cell vaccines for solid tumors

Immunotherapy, particularly immune checkpoint inhibitors (ICIs) programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), has heralded a new era of tumor treatment. Although ICIs have clinical benefits, their complex heterogeneity and diverse...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Yuting Li, Abudukadierjiang Abudureheman, Jianming Xu
Natura: Artigo
Lingua:Inglês
Pubblicazione: China Anti-Cancer Association 2025-10-01
Serie:Cancer Biology & Medicine
Soggetti:
neoantigen
dendritic cell
vaccines
immunotherapy
solid tumor
Accesso online:https://www.cancerbiomed.org/content/22/10/1143
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi